Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
Open Access
- 30 March 2016
- journal article
- review article
- Published by Wiley in Clinical and Translational Science
- Vol. 9 (2), 89-104
- https://doi.org/10.1111/cts.12391
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Global cancer transitions according to the Human Development Index (2008–2030): a population-based studyThe Lancet Oncology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challengesStatistics in Medicine, 2010
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI Journal of the National Cancer Institute, 2009
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Cancer immunoediting from immune surveillance to immune escapeImmunology, 2007